Vanguard Group Inc Gain Therapeutics, Inc. Call Options Transaction History
Vanguard Group Inc
- $5.46 Trillion
- Q3 2024
Call Options
0 transactions
| Quarter | Operation | Price Per call | calls change | calls Held | SEC Form |
|---|
Others Institutions Holding GANX
# of Institutions
23Shares Held
2.39MCall Options Held
10KPut Options Held
0-
David Einhorn Greenlight Capital Inc | New York, Ny588KShares$917,9190.1% of portfolio
-
Dme Capital Management, LP New York, NY566KShares$883,1620.04% of portfolio
-
Joel Greenblatt Gotham Asset Management, LLC | New York, Ny335KShares$521,9630.01% of portfolio
-
Geode Capital Management, LLC Boston, MA272KShares$424,2760.0% of portfolio
-
Telemetry Investments, L.L.C. New York, NY123KShares$191,8800.61% of portfolio
About Gain Therapeutics, Inc.
- Ticker GANX
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 11,883,400
- Market Cap $18.5M
- Description
- Gain Therapeutics, Inc., a biotechnology company, engages in developing various therapies to treat diseases caused by protein misfolding. It focuses on rare genetic diseases and neurological disorders. The company uses its Site-Directed Enzyme Enhancement Therapy platform to discover allosteric sites on misfolded proteins and identify proprietar...